Both in Biotechnology
Intensity Therapeutics vs TScan Therapeutics
Over the past year INTS returned −46.3% and TCRX returned −90.7%; their daily moves had a correlation of 0.06.
INTS −46.3% TCRX −90.7%Growth of $1, one year, split-adjusted
| Metric | INTS | TCRX |
|---|---|---|
| Price | $3.38 | $0.1989 |
| Market cap | $11.0M | $13.5M |
| Today | +6.29% | +3.59% |
| 1 month | −1.2% | −37.4% |
| 6 months | −34.4% | −82.7% |
| Year to date | −67.0% | −80.1% |
| 1 year | −44.7% | −91.3% |
| Revenue growth (YoY) | — | −65.8% |
| Gross margin | — | 100.0% |
| Net margin | — | −2888.6% |
| P/E (TTM) | — | — |
| Price / sales | — | 1.9× |
| Net cash | $9.5M | $67.4M |
| Dividend yield | — | — |
| Volatility (60d) | 62.5% | 140.0% |
| Short % of float | 2.9% | 4.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).